drugset / Trial / NCT01009853

Steady State Study of Codeine Sulfate

NCT01009853

Phase 1 Completed 34 enrolled Roxane Laboratories
NaSingle-groupOpen-labelTreatment

Summary

Study to characterize the steady-state pharmacokinetics of codeine and its metabolites morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) after oral administration of Roxane Laboratories' codeine sulfate tablets administered at a dose of 15 mg Q4H x 5 days.

Timeline

Start
2008-01
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Codeine Small molecule 15 mg Oral

Indications

No indication recorded.